BCC
CORT icon

Bridge City Capital’s Corcept Therapeutics CORT Stock Holding History

Bridge City Capital’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.68M Sell
53,823
-1,051
-2% -$63.5K 1.07% 30
2026
Q1 		$2.21M Buy
54,874
+25,339
+86% +$947K 0.61% 67
2025
Q4 		$1.03M Buy
29,535
+10,324
+54% +$811K 0.3% 93
2025
Q3 		$1.6M Sell
19,211
-331
-2% -$24K 0.43% 87
2025
Q2 		$1.43M Sell
19,542
-22,487
-54% -$1.63M 0.4% 90
2025
Q1 		$4.8M Sell
42,029
-15,863
-27% -$966K 1.44% 20
2024
Q4 		$2.92M Buy
57,892
+518
+0.9% +$27.1K 0.78% 57
2024
Q3 		$2.66M Buy
57,374
+8,137
+17% +$289K 0.73% 65
2024
Q2 		$1.6M Sell
49,237
-401
-0.8% -$11K 0.54% 80
2024
Q1 		$1.25M Buy
49,638
+386
+0.8% +$9.12K 0.46% 88
2023
Q4 		$1.6M Buy
49,252
+5,767
+13% +$158K 0.62% 78
2023
Q3 		$1.18M Sell
43,485
-17,147
-28% -$496K 0.6% 80
2023
Q2 		$1.35M Buy
60,632
+35
+0.1% +$806 0.64% 74
2023
Q1 		$1.31M Sell
60,597
-227
-0.4% -$4.98K 0.66% 76
2022
Q4 		$1.24M Sell
60,824
-430
-0.7% -$10.8K 0.63% 79
2022
Q3 		$1.57M Sell
61,254
-22,564
-27% -$604K 0.86% 54
2022
Q2 		$1.99M Sell
83,818
-149
-0.2% -$3.25K 1.05% 44
2022
Q1 		$1.89M Sell
83,967
-441
-0.5% -$9.38K 0.88% 55
2021
Q4 		$1.67M Sell
84,408
-15
-0% -$304 0.69% 73
2021
Q3 		$1.66M Sell
84,423
-22,515
-21% -$471K 0.75% 69
2021
Q2 		$2.35M Sell
106,938
-3,574
-3% -$79.5K 0.8% 63
2021
Q1 		$2.63M Sell
110,512
-1,127
-1% -$30.1K 0.87% 53
2020
Q4 		$2.92M Sell
111,639
-1,159
-1% -$24.4K 1.11% 44
2020
Q3 		$1.96M Buy
112,798
+21,938
+24% +$350K 0.94% 53
2020
Q2 		$1.53M Buy
+90,860
New +$1.28M 0.7% 68

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bridge City Capital's CORT Position: Q2 2026 in Review

Bridge City Capital reduced its Corcept Therapeutics (CORT) stake by 1.9% in Q2 2026, selling an estimated $63.5K and leaving 53,823 shares worth $4.68M. The position accounts for 1.07% of the portfolio, ranked #30.

Bridge City Capital first reported a position in CORT in Q2 2020 and has held it in 25 quarters since. The position peaked at $4.8M in Q1 2025. 423 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Bridge City Capital held 53,823 shares of Corcept Therapeutics worth $4.68M as of Q2 2026.
  • Bridge City Capital sold 1,051 Corcept Therapeutics shares in Q2 2026, an estimated $63.5K.
  • Corcept Therapeutics made up 1.07% of Bridge City Capital's portfolio in Q2 2026, its #30 holding.
  • Bridge City Capital first reported a position in Corcept Therapeutics in Q2 2020 and has held it in 25 quarters since.
  • Bridge City Capital's Corcept Therapeutics position peaked at $4.8M in Q1 2025.
  • 423 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Bridge City Capital's 13F filing for Q2 2026, filed 11 Aug 2026.